PMID- 32547040
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1176-6336 (Print)
IS  - 1178-203X (Electronic)
IS  - 1176-6336 (Linking)
VI  - 16
DP  - 2020
TI  - Neutrophil-Lymphocyte Ratio (NLR) for Predicting Clinical Outcomes in Patients 
      with Coronary Artery Disease and Type 2 Diabetes Mellitus: A Propensity Score 
      Matching Analysis.
PG  - 437-443
LID - 10.2147/TCRM.S244623 [doi]
AB  - BACKGROUND: Cardiovascular diseases (CVD) combined with Type 2 diabetes mellitus 
      (T2DM) frequently occurred. In this study, we aimed at exploring the prognostic 
      significance of blood neutrophil-lymphocyte ratio (NLR) in these types of 
      patients. PATIENTS AND METHODS: Between June 30, 2010 and August 30, 2017, 1454 
      patients with CVD were enrolled in this study. Kaplan and Meier methodology was 
      used for survival analysis. We also used propensity score matching (PSM) to 
      further compare survival in patients with or without T2DM. RESULTS: Among all 
      patients, we applied ROC curve analysis to stratify all patients into two 
      different groups including NLR >2.5 (n=432) and NLR</= 2.5 (n=1022) groups. After 
      that, we further performed survival analysis between different groups. We found 
      that patients with NLR </=2.5 had significantly favorable OS compared with the 
      overall survival in patients with NLR >2.5. We further built the PSM using 242 
      pairs of patients who have CVD and with or without T2DM. After adjusting for 
      competing risk factors, we performed Cox proportional hazards models to identify 
      the independent prognostic factors in multivariable adjustment. We found that NLR 
      </=2.5 (HR: 2.576, 95% CI: 1.241-4.583, P =0.001) and extent of coronary artery 
      disease (HR: 2.432, 95% CI: 1.189-4.392, P =0.005) remained independent 
      predictors of OS. CONCLUSION: In conclusion, we have established an PSM model and 
      found that a high NLR value was an independent prognostic factor for survival, 
      predicting in patients with both CAD and T2DM. The NLR value would be a valuable 
      biomarker to evaluate the outcomes of patients and give them opportunities for 
      choosing alternative therapies.
CI  - (c) 2020 Qiao et al.
FAU - Qiao, Shang
AU  - Qiao S
AD  - Department of Cardiology, Bayan Nur Hospital of the Nei Monggol Autonomous 
      Region, Bayan Nur City 015000, People's Republic of China.
FAU - Gao, Wen
AU  - Gao W
AD  - Department of Cardiology, Bayan Nur Hospital of the Nei Monggol Autonomous 
      Region, Bayan Nur City 015000, People's Republic of China.
FAU - Guo, Shujun
AU  - Guo S
AD  - Department of Cardiology, Bayan Nur Hospital of the Nei Monggol Autonomous 
      Region, Bayan Nur City 015000, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200519
PL  - New Zealand
TA  - Ther Clin Risk Manag
JT  - Therapeutics and clinical risk management
JID - 101253281
PMC - PMC7245465
OTO - NOTNLM
OT  - CVD
OT  - NLR
OT  - T2DM
OT  - cardiovascular diseases
OT  - neutrophil-lymphocyte ratio
OT  - type 2 diabetes mellitus
COIS- The authors who have taken part in this study declared that they have nothing to 
      disclose regarding funding or conflict of interest with respect to this 
      manuscript.
EDAT- 2020/06/18 06:00
MHDA- 2020/06/18 06:01
PMCR- 2020/05/19
CRDT- 2020/06/18 06:00
PHST- 2020/01/03 00:00 [received]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/06/18 06:00 [entrez]
PHST- 2020/06/18 06:00 [pubmed]
PHST- 2020/06/18 06:01 [medline]
PHST- 2020/05/19 00:00 [pmc-release]
AID - 244623 [pii]
AID - 10.2147/TCRM.S244623 [doi]
PST - epublish
SO  - Ther Clin Risk Manag. 2020 May 19;16:437-443. doi: 10.2147/TCRM.S244623. 
      eCollection 2020.